

=> d his

(FILE 'HOME' ENTERED AT 14:23:17 ON 19 MAR 2003)

FILE 'EUROPATFULL, PCTFULL, USPAT2, WPIDS' ENTERED AT 14:23:44 ON 19 MAR 2003

FILE 'EUROPATFULL, PCTFULL, USPATFULL, USPAT2, WPIDS' ENTERED AT
14:23:53
ON 19 MAR 2003

L1	1115 S SILDENAFIL OR VIAGRA
L2	1881 S PHENTOLAMINE
L3	147 S L1(S)L2
L4	46 S L3(S)ALPROSTADIL
L5	4 S L4 NOT PY>=2000

7 ANSWER 4 OF 7 PCTFULL COPYRIGHT 2003 Univentio
 ACCESSION NUMBER: 1999059584 PCTFULL ED 20020515
 TITLE (ENGLISH): COMBINATION OF PHENTOLAMINE AND CYCLIC GMP
 PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF
 SEXUAL DYSFUNCTION
 TITLE (FRENCH): COMBINAISON DE PHENTOLAMINE ET D'INHIBITEURS DE LA
 PHOSPHODIESTERASE GMP CYCLIQUE UTILISES DANS LE
 TRAITEMENT DES DYSFONCTIONS SEXUELLES
 INVENTOR(S): ESTOK, Thomas, Mark
 PATENT ASSIGNEE(S): SCHERING CORPORATION;
 ESTOK, Thomas, Mark
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE

WO 9959584	A1	19991125

DESIGNATED STATES
 W:

AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE
 ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR
 LT LU LV MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK
 SL TJ TM TR TT UA US US US UZ VN YU ZA GH GM KE LS MW
 SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
 DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG
 CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 1999-US7046 A 19990517
 PRIORITY INFO.: US 1998-09/081,640 19980520
 US 1998-09/082,977 19980521
 US 1998-09/106,517 19980629

CLMEN 5 The composition of claim 1 wherein the **phentolamine** is
phentolamine mesylate and the cGMP PIDE V inhibitor is
sildenafil citrate.

10 The method of claim 6 wherein the phentolarnine is
phentolamine mesylate and the cGMP PDE inhibitor V is
sildenafil citrate.

L5 ANSWER 4 OF 4 PCTFULL COPYRIGHT 2003 Univentio
 ACCESSION NUMBER: 1999002164 PCTFULL ED 20020515
 TITLE (ENGLISH): METHOD AND COMPOSITION FOR TREATMENT OF ERECTILE
 DYSFUNCTION
 TITLE (FRENCH): PROCEDE ET COMPOSITION POUR LE TRAITEMENT DE LA
 DYSERECTION
 INVENTOR(S): STJERNSCHANTZ, Johan;
 RESUL, Bahram
 PATENT ASSIGNEE(S): PHARMACIA & UPJOHN AB;
 STJERNSCHANTZ, Johan;
 RESUL, Bahram
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9902164	A1	19990121

DESIGNATED STATES

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
 ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS
 LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG
 SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS
 MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
 DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG
 CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 1998-SE1367 A 19980710
 PRIORITY INFO.: SE 1997-9702681-9 19970710

DETD . . . bromocriptine has also been used, as well as
 antiserotonergic agents such as trazodone, ketanserin and mianserin.
 Recently, a
 selective type 5-phosphodiesterase inhibitor **sildenafil**
 (Viagra[®]) has been approved
 for clinical use. In addition there are many other drugs that have been
 tested and used
 for the treatment of erectile dysfunction. Drugs given locally include
 e.g. papaverine, a
 smooth muscle relaxing agent, and **phentolamine**, an
 alpha-adrenergic antagonist as
 well as prostaglandins, particularly prostaglandin E₁ (PGE₁;
alprostadil). These drugs
 relax smooth muscle, thus promoting the development of erection, and
 are
 given by
 local injection into the cavernous tissue of the . . . sensation in
 about 35 % of the patients, and 11 % of the patients reported pain
 after every treatment
 with **alprostadil** (Padma-Nathan et al., 1997). It is thus
 obvious that local pain
 constitutes one of the most significant side-effects of PGEI, and. .